Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Moderna Covid vaccine could have similar results to Pfizer drug, Fauci says

US infectious disease expert says ‘extraordinary’ results could suggest second vaccine will be available

Alex Woodward
New York
Monday 09 November 2020 16:54 GMT
Comments
Coronavirus in numbers
Leer en Español

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Positive results from a potential coronavirus vaccine announced by the drug maker Pfizer could indicate that two vaccines will be available, as biotech firm Moderna has relied on similar technology to produce its drug, according to Dr Anthony Fauci.

The nation’s leading infectious disease expert told The Washington Post that Pfizer’s reported results of a “90 per cent effective” vaccine are “really quite good, I mean extraordinary.”

Pfizer’s 44,000-person trial has found 94 cases of Covid-19 among patients who had not been previously infected. Fewer than nine patients among those who had the coronavirus received two shots of the vaccine.

The company announced its findings in a press release; the data has not been peer reviewed or published in a medical journal.

Pfizer said it not participate in Donald Trump’s Operation Warp Speed drug development programme, though vice president Mike Pence, who leads the White House coronavirus task force, attributed the company’s results to the “public-private partnership forged by the president."

"We were never part of the Warp Speed,” Kathrin Jansen, a senior vice president and the head of vaccine research and development at Pfizer, said on Monday. “We have never taken any money from the US government, or from anyone.”

But the company did receive a $2bn contract from the government to provide 100 million doses if the drug proved effective.

Eleven vaccine candidates are in late-stage trials; four are being developed in the US.

Moderna is among several firms that joined the president’s initiative, which set out to put several manufacturers and pharmaceutical companies in motion with federal financial support to rapidly produce vaccine candidates.

Results from a vaccine in drug trial phase from Moderna, supported by research from the National Institute of Allergy and Infectious Diseases, could be released within weeks.

Pfizer, which developed its vaccine with German firm BioNTech, is expected to submit an application to the Food and Drug Administration for emergency drug authorisation by the end of November.

President-elect Joe Biden, who was declared the victory in a campaign against Mr Trump in the 2020 presidential race, has announced a 13-member coronavirus advisory board to begin implementing a “blueprint” to tackle the crisis before he enters office in January.

The disease has infected more than 10 million Americans and killed nearly 240,000 since the onset of the outbreak. Health officials and analysts have warned that the virus is spreading at unprecedented rates, with seven-day average infections reached more than 110,000, while daily case counts broke record highs in at least four consecutive days last week.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in